Gossamer Bio prices IPO
Biotech Gossamer Bio. Inc. , an immunology- and oncology-focused company with six drugs in its pipeline, priced its initial public offering of 17.25 million shares at $16 a share Thursday evening. The sale of the shares will raise about $276 million. Shares are expected to begin trading Friday morning on the Nasdaq under the ticker symbol "GOSS." Bank of America Merrill Lynch, SVB Leerink, Barclays and Evercore ISI are the underwriters on the deal. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.